4-(4'-(hydroxy(diphenyl)methyl)piperidin-1-yl)-1-(4-methylphenyl)butan-1-ol | 1057649-28-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(4'-(hydroxy(diphenyl)methyl)piperidin-1-yl)-1-(4-methylphenyl)butan-1-ol
• 英文别名: 1-(4-methyl)-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butan-1-ol；4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)-1-(p-tolyl)butan-1-ol；KSC-335-077；4-[4-[Hydroxy(diphenyl)methyl]-1-piperidyl]-1-(p-tolyl)butan-1-ol；4-[4-[hydroxy(diphenyl)methyl]piperidin-1-yl]-1-(4-methylphenyl)butan-1-ol
• CAS: 1057649-28-1
• 化学式: C₂₉H₃₅NO₂
• 分子量: 429.602
• InChiKey: RFFMHTMETSZPCX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.3
• 重原子数：
  32
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  43.7
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  4-(4'-(hydroxy(diphenyl)methyl)piperidin-1-yl)-1-(4-methylphenyl)butan-1-one 在 sodium tetrahydroborate 作用下， 以 甲醇 为溶剂， 反应 1.0h， 以45%的产率得到4-(4'-(hydroxy(diphenyl)methyl)piperidin-1-yl)-1-(4-methylphenyl)butan-1-ol
  参考文献：
  名称：

  Identification of Terfenadine as an Inhibitor of Human CD81-Receptor HCV-E2 Interaction: Synthesis and Structure Optimization

  摘要：

  特非那定（4-[4-（羟二苯甲基）-1-哌啶基]-1-（4-叔丁基苯基）-丁烷-1-醇）在生物筛选中被识别为中等抑制剂（抑制率为27%），针对CD81-LEL与HCV-E2的相互作用。为了提高观察到的生物活性，通过微波辅助亲核取代合成了63个特非那定衍生物。这些制备的化合物通过使用HUH7.5细胞的荧光标记抗体检测法测试了它们的抑制效力。可以得出明显的结构-活性关系。优化取得了成功，导致了3g的识别，这是最强效的化合物（抑制率为69%）。对病毒颗粒的实验揭示可能存在额外的降低HCV感染的机制。

  DOI：

  10.3390/molecules13051081

文献信息

• METHODS AND COMPOSITIONS FOR TREATING INFECTION
  申请人：UNIVERSITY OF ROCHESTER

  公开号：US20150238473A1

  公开（公告）日：2015-08-27

  Provided herein are compositions and methods for treating or preventing infection.

  本文提供了用于治疗或预防感染的组合物和方法。
• NOVEL CHIRAL METAL COMPLEX AND USE THEREOF FOR ANALYZING CHIRALITY OF CHARGED COMPOUND BY 1H NMR SPECTROSCOPY
  申请人：KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY

  公开号：US20170052131A1

  公开（公告）日：2017-02-23

  Provided are novel ligand, a chiral metal complex including the same, and a use of the chiral metal complex for analyzing the chirality of a charged compound by 1 H NMR spectroscopy. The chiral metal complex of the present invention may be used as the chiral solvating agent to conveniently analyze the optical purity of charged compounds such as various amine derivatives, carboxylic acid derivatives, cyanohydrin derivatives and charged metal complexes by 1 H NMR spectroscopy.

  本发明提供了一种新型配体，包括该配体的手性金属配合物，以及利用该手性金属配合物通过1H NMR光谱分析带电化合物的手性的用途。本发明的手性金属配合物可用作手性溶剂化剂，方便地通过1H NMR光谱分析各种胺衍生物、羧酸衍生物、氰醇衍生物和带电金属配合物等带电化合物的光学纯度。
• Methods and compositions for treating infection
  申请人：UNIVERSITY OF ROCHESTER

  公开号：US10004701B2

  公开（公告）日：2018-06-26

  Provided herein are compositions and methods for treating or preventing infection.

  本文提供了用于治疗或预防感染的组合物和方法。
• Repurposing the Antihistamine Terfenadine for Antimicrobial Activity against <i>Staphylococcus aureus</i>
  作者：Jessamyn I. Perlmutter、Lauren T. Forbes、Damian J. Krysan、Katherine Ebsworth-Mojica、Jennifer M. Colquhoun、Jenna L. Wang、Paul M. Dunman、Daniel P. Flaherty

  DOI：10.1021/jm5010682

  日期：2014.10.23

  Staphylococcus aureus is a rapidly growing health threat in the U.S., with resistance to several commonly prescribed treatments. A high-throughput screen identified the antihistamine terfenadine to possess, previously unreported, antimicrobial activity against S. aureus and other Gram-positive bacteria. In an effort to repurpose this drug, structure-activity relationship studies yielded 84 terfenadine-based analogues with several modifications providing increased activity versus S. aureus and other bacterial pathogens, including Mycobacterium tuberculosis. Mechanism of action studies revealed these compounds to exert their antibacterial effects, at least in part, through inhibition of the bacterial type II topoisomerases. This scaffold suffers from hERG liabilities which were not remedied through this round of optimization; however, given the overall improvement in activity of the set, terfenadine-based analogues provide a novel structural class of antimicrobial compounds with potential for further characterization as part of the continuing process to meet the current need for new antibiotics.
• PROCESS FOR PRODUCTION OF PIPERIDINE DERIVATIVES
  申请人：Meckler Harold

  公开号：US20090124810A1

  公开（公告）日：2009-05-14

  Processes are disclosed for preparing piperidine derivative compounds of the formulae I, II or III: The processes involve reacting a compound of formula Ia, IIa or IIIa with isobutyrate or an isobutyrate equivalent.